Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067569 | 0.86 | POLB (0.39) | MAPTALDH1A1GAA | |
| SCHEMBL5067567 | 0.86 | POLB (0.39) | MAPTALDH1A1GAA | |
| SCHEMBL5009722 | 0.84 | MAPT (0.45) | MAPTALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL379473 | 0.83 | MAPT (0.44) | MAPTALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL12286642 | 0.82 | ALDH1A1 (0.43) | MAPTALDH1A1GAATSHRKDM4E | |
| SCHEMBL18792830 | 0.82 | ALDH1A1 (0.43) | MAPTALDH1A1GAATSHRKDM4E | |
| SCHEMBL19893800 | 0.80 | MAPT (0.47) | MAPTALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL19909758 | 0.80 | MAPT (0.47) | MAPTALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL4222468 | 0.80 | MAPT (0.47) | MAPTALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL379518 | 0.80 | MAPT (0.42) | MAPTALDH1A1GAATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| CN-1742013-A | Pyrazolopyrimidine compound and method for producing the same | TANABE SEIYAKU CO (JP) | 2006-03-01 | — | — | CN | disclosed |
| EP-1585481-A2 | PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004064721-A2 | A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | MAPT 4212/4885ALDH1A1 2470/4885GAA 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.